PMID- 25713417
OWN - NLM
STAT- MEDLINE
DCOM- 20150727
LR  - 20151119
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 68
IP  - 6
DP  - 2015 Jun
TI  - LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell 
      leukaemia/small lymphocytic B cell lymphoma.
PG  - 473-8
LID - 10.1136/jclinpath-2015-202862 [doi]
AB  - AIMS: Chronic lymphocytic B cell leukaemia (CLL)/small lymphocytic B cell 
      lymphoma (SLL) has proven to be not a uniform entity but to consist of various 
      disease subtypes. CLL might also pose diagnostic challenges by demonstrating an 
      uncommon immunohistochemical profile. Recently, the role of lymphocyte 
      enhancer-binding factor 1 (LEF1) in CLL was elucidated being highly expressed and 
      seeming to have a prognostic value. Our aim was to test the applicability of LEF1 
      as marker for CLL in a diagnostic setting. METHODS: We investigated LEF1 
      expression in lymphomas by immunohistochemistry on tissue microarrays containing 
      several lymphoma entities (altogether 720 cases, including 61 CLL cases). We also 
      separated CLL cases by zeta-chain-associated protein kinase 70 (ZAP70) and CD38 
      stainings and fluorescence in situ hybridisation analyses for TP53 deletions and 
      trisomy 12 into respective groups and correlated data with LEF1 expression. 
      RESULTS: The area under the receiver operating characteristic curve for LEF1 as a 
      diagnostic marker for CLL was 0.815 (95% CI 0.742 to 0.888). The relevant 
      diagnostic cut-off value for LEF1 positivity determined by the Youden's index was 
      10% (specificity 92%, sensitivity 70%). The majority of CLL cases (70%) expressed 
      LEF1. Eighteen per cent of (transformed) diffuse large B cell lymphoma cases also 
      expressed LEF1. In most other lymphoma entities, LEF1 was negative. There was a 
      positive correlation of LEF1 staining with ZAP70 expression (Spearman's rho: 
      0.438, p<0.001), but not with CD38 expression, TP53 deletions or trisomy 12. 
      CONCLUSIONS: LEF1 is a useful marker in the differential diagnosis of CLL in 
      difficult cases. It shows a high specificity (92%) and a reasonable sensitivity 
      (70%) for this entity.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Menter, Thomas
AU  - Menter T
AD  - Institute of Pathology, University Hospital Basel, Basel, Switzerland.
FAU - Dirnhofer, Stephan
AU  - Dirnhofer S
AD  - Institute of Pathology, University Hospital Basel, Basel, Switzerland.
FAU - Tzankov, Alexandar
AU  - Tzankov A
AD  - Institute of Pathology, University Hospital Basel, Basel, Switzerland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20150224
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (LEF1 protein, human)
RN  - 0 (Lymphoid Enhancer-Binding Factor 1)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis
MH  - Lymphoid Enhancer-Binding Factor 1/*metabolism
MH  - Male
MH  - Middle Aged
MH  - ROC Curve
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - DIAGNOSTICS
OT  - HAEMATOPATHOLOGY
OT  - IMMUNOHISTOCHEMISTRY
OT  - IMMUNOPHENOTYPING OF LEUKAEMIAS/LYMPHOMAS
OT  - LEUKAEMIA
EDAT- 2015/02/26 06:00
MHDA- 2015/07/28 06:00
CRDT- 2015/02/26 06:00
PHST- 2015/01/05 00:00 [received]
PHST- 2015/02/05 00:00 [accepted]
PHST- 2015/02/26 06:00 [entrez]
PHST- 2015/02/26 06:00 [pubmed]
PHST- 2015/07/28 06:00 [medline]
AID - jclinpath-2015-202862 [pii]
AID - 10.1136/jclinpath-2015-202862 [doi]
PST - ppublish
SO  - J Clin Pathol. 2015 Jun;68(6):473-8. doi: 10.1136/jclinpath-2015-202862. Epub 
      2015 Feb 24.